Intermittent fasting entails restricting food intake during specific times of day, days of the week, religious practice, or surrounding clinically important events. Herein, the metabolic and circadian rhythm mechanisms underlying the proposed benefits of intermittent fasting for the cancer population are described. We summarize epidemiological, preclinical, and clinical studies in cancer published between January 2020 and August 2022 and propose avenues for future research. An outstanding concern regarding the use of intermittent fasting among cancer patients is that fasting often results in caloric restriction, which can put patients already prone to malnutrition, cachexia, or sarcopenia at risk. Although clinical trials do not yet provide sufficient data to support the general use of intermittent fasting in clinical practice, this summary may be useful for patients, caregivers, and clinicians who are exploring intermittent fasting as part of their cancer journey for clinical outcomes and symptom management.
CITATION STYLE
Kalam, F., James, D. L., Li, Y. R., Coleman, M. F., Kiesel, V. A., Cespedes Feliciano, E. M., … Kleckner, A. S. (2023). Intermittent fasting interventions to leverage metabolic and circadian mechanisms for cancer treatment and supportive care outcomes. Journal of the National Cancer Institute. Monographs, 2023(61), 84–103. https://doi.org/10.1093/jncimonographs/lgad008
Mendeley helps you to discover research relevant for your work.